炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：融中财经 导读 THECAPITAL 当前，股权投资行业正步入认知回归与能力重塑的"淬炼期"：长期资本持续扩容，耐心资本日益成为支 撑科技创新的核心力量，投资机构聚焦硬科技与战略性新兴产业，深化布局、深挖价值；多元退出与投 资路径不断拓展，加速构建"投早、投小、投科技"的良性生态；政府引导基金与国资投资平台已成长为 产业发展的"稳定器"与"助推器"，携手产业方及各类资本，共建深度融合、共创共享的产融生态。 作为"十五五"规划的开局之年，融中第十五届中国资本年会暨大虹桥科创投资大会应势启幕。本届峰会 以《淬·炼》为主题，汇聚政府部门代表、头部投资机构、顶尖经济学家及行业领军企业，于新年伊始 展开深度对话，共议投资趋势、产业发展与科技创新前沿，致力于打造覆盖出资人、投资人与企业端的 高效产融生态圈，推动投资产业链全链条融合与价值贯通。 2026年1月13日上午，"【2026】科技突围和经济转型下的投资新逻辑"圆桌论坛开启，弘毅投资总裁曹 永刚、华映资本创始管理合伙人季薇、国科嘉和董事长&管理合伙人王戈、鼎晖投资创始合伙人&鼎晖 VGC ...

Group 1 - The core viewpoint emphasizes that future investments in the pharmaceutical sector should focus on the intrinsic logic of clinical value [1] - The pharmaceutical and biotechnology sectors are driven by innovation (overseas expansion, AI, new technologies), performance validation, policy dividends, and the spring market effect, with a short-term focus on innovative drugs and CXO [1] - High elasticity sub-themes include AI healthcare/AI pharmaceuticals, brain-computer interfaces, and small nucleic acid drugs, while the innovative drug industry chain and innovative medical devices are viewed positively [1] Group 2 - In the innovative medical device sector, there is optimism regarding the upgrade of high-end medical devices and high-value consumables [1] - With the global return to a rate-cutting cycle and structural policy shifts domestically, medical insurance negotiations support innovative drugs, and centralized procurement stabilizes industry profitability [1] - The valuation of the pharmaceutical sector is expected to steadily recover from the first quarter of 2025, with a clear trend of industrial quality improvement and enhanced international competitiveness [1] Group 3 - The Guotai ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20% [1] - This index focuses on the innovative biopharmaceutical field, selecting listed companies involved in biotechnology, pharmaceuticals, and related medical services to reflect the overall performance of innovative biopharmaceutical securities [1]

Policy Developments - The National Healthcare Security Administration has issued a guideline for the pricing of surgical and treatment auxiliary operations, focusing on medical technology innovations such as robotic surgery and 3D printing, establishing 37 pricing items and guiding the transition from traditional to precision medicine [2] Drug and Device Approvals - Bailitianheng's drug application for iza-bren, a first-in-class EGFR×HER3 dual antibody ADC for treating recurrent or metastatic esophageal squamous cell carcinoma, has been accepted and prioritized for review by the National Medical Products Administration [4] - Heng Rui Medicine has received clinical trial approval for SHR-9839, a humanized antibody for advanced solid tumors, and HRS-4642, a KRAS G12D inhibitor [5] - Fosun Pharma's subsidiary has been approved to conduct clinical trials for HLX701 in combination with chemotherapy for advanced colorectal cancer [6] Capital Market Activities - InnoCare Pharma has entered a collaboration agreement with Shenzhen Hengtai Biotechnology for the ISM8969 project, a new NLRP3 inhibitor for CNS diseases, with a potential total payment of up to $66 million [8][9] - Zhejiang Dejin Bio completed a multi-million A round financing to advance its core product, a recombinant botulinum toxin, and for international expansion [10] Industry Developments - Ant Group's Antifor has launched a DeepSearch feature on its PC platform to assist medical professionals with literature searches and clinical diagnosis [12] - Guangzhou's political advisor has proposed a plan to develop the brain-computer interface industry, aligning with national strategies and leveraging local resources [13] Shareholder Actions - Meihua Medical announced that shareholders plan to reduce their holdings by up to 2.51% of total shares due to personal financial needs [15] - Kain Technology has voluntarily withdrawn its drug registration application for a new hepatitis B indication, which will impact its 2025 profits [16]

Core Viewpoint - The recent delisting of SPACs associated with Chinese companies has halted their plans for U.S. listings, highlighting the risks of the SPAC model and the unique value of the OTC market [1] Group 1: SPAC Delisting and Its Implications - Nasdaq delisted 13 securities on January 13, including three SPACs (Four Leaf, DT Cloud, AlphaTime) linked to Chinese companies, transferring them to the OTC market [1] - The delisting exposes the vulnerabilities of the SPAC model, particularly the reliance on the SPAC's continued listing status [4] - The case of Xiaoyu Tidata illustrates that even with stable business operations, a SPAC's delisting can abruptly halt the entire listing process [4] Group 2: Regulatory Changes and Challenges - New Nasdaq regulations effective January 17, 2026, will raise the minimum public float market value requirement from $5 million to $15 million and mandate that SPAC mergers must raise at least $25 million in public funds [4] - These regulatory changes create significant barriers for many small and medium-sized enterprises [4] Group 3: Advantages of the OTC Market - The OTC market offers a crucial buffer, allowing SPACs to continue merger transactions even after delisting from the main board [5] - OTC has lower financial requirements, with no strict profitability criteria and minimal annual fees ranging from a few thousand to $20,000 [6] - The listing process on the OTC market can be completed in 3-6 months, significantly faster than the 12-24 months required for a Nasdaq IPO [7] Group 4: Structured Compliance and Growth Opportunities - The OTC market features a four-tier compliance structure, catering to different stages of company development [8] - Companies already listed on domestic boards can issue ADRs on OTCQX without meeting stringent SEC registration requirements, facilitating exposure to U.S. investors [9] - The OTC market serves as a "golden stepping stone" for companies aiming to transition to Nasdaq or NYSE, with approximately 15% of Nasdaq-listed companies having previously grown on the OTC market [10] Group 5: Diverse Financing Options - The OTC market supports various financing methods, including private placements and convertible bonds, which are particularly suitable for light-asset companies in technology and biomedicine [11] - Companies can leverage the OTC market to access global financing while providing liquidity options for early investors [11] - The current delisting trend reinforces the need for Chinese companies to consider paths beyond the main board for U.S. listings [11]

Core Viewpoint - The economic performance of Shanghai in 2025 shows a positive trend in emerging industries, with a GDP growth of 5.4% and significant increases in industrial output and investment [3][4]. Economic Performance - In 2025, Shanghai's GDP reached 56,708.71 billion yuan, reflecting a year-on-year growth of 5.4% at constant prices [3]. - The industrial added value in Shanghai grew by 5.0%, with the total industrial output value increasing by 4.6% [3]. - Key sectors such as railway, shipbuilding, aerospace, and other transportation equipment manufacturing saw a remarkable growth of 15.8% [3]. Investment Trends - Fixed asset investment in Shanghai's industrial sector rose by 20.0%, significantly outpacing the overall fixed asset investment growth rate by 15.4 percentage points [3]. - The three leading industries in Shanghai's manufacturing sector achieved a year-on-year output growth of 9.6%, surpassing 2 trillion yuan in total scale [4]. Emerging Industries - The integrated circuit manufacturing sector experienced a growth of 15.1%, while artificial intelligence manufacturing grew by 13.6% in 2025 [4]. - Strategic emerging industries in Shanghai saw a 6.5% increase in output, with the new energy sector growing by 12.9% and high-end equipment manufacturing by 11.1% [4]. Industrial Strategy - Shanghai aims to enhance its industrial structure by focusing on advanced manufacturing, with a modern industrial system framework of "2+3+6+6" [5]. - The three leading industries identified are integrated circuits, biomedicine, and artificial intelligence, which are expected to drive industrial development during the 14th Five-Year Plan period [5]. AI Industry Developments - In a recent month, five AI companies in Shanghai went public, indicating a robust growth trajectory in the AI sector [5]. - Shanghai's local AI company, Xiyu Technology, became the fastest AI company globally to reach IPO status, highlighting the rapid development in this field [5]. Integrated Circuit Industry - Shanghai has established a comprehensive integrated circuit industry chain, excelling in chip design, manufacturing, and testing, with 35 listed companies on the Sci-Tech Innovation Board [7]. - The city is a leader in chip design and manufacturing, with advancements in packaging and high-end equipment materials supporting the growth of AI chip enterprises [7].

Core Insights - Shandong province is focusing on industrial economic development as a key strategy, aiming for a significant increase in industrial product exports by 2025, targeting 1.97 trillion yuan with a growth rate of 4.4% [1] - The province is emphasizing high-end, intelligent, and digital transformation in manufacturing, with notable growth projections for various sectors, including a 47% increase in high-end equipment exports [1] - Key industrial clusters such as steel, non-ferrous metals, and petrochemicals are expected to see substantial improvements, with specific export growth rates projected for steel, aluminum, and refined oil products [2] Industrial Development - By 2025, Shandong aims to export industrial products worth 1.97 trillion yuan, with machinery and electrical products expected to reach 1.06 trillion yuan, marking an 8.7% growth [1] - High-end equipment exports are projected to reach 108.96 billion yuan, growing by 47%, while electronic information exports are expected to grow by 30% [1] - The province is implementing policies to enhance production capabilities and streamline customs processes for biopharmaceuticals and medical instruments [1] Key Industry Clusters - Major industries such as steel, non-ferrous metals, and petrochemicals are set to improve quality and efficiency, with steel, aluminum, and refined oil exports projected to grow by 3.3%, 7%, and 29.5% respectively by 2025 [2] - Shandong has 105 categories of electromechanical products that rank first in national export value, with certain products like diesel trucks and concrete mixers accounting for over 10% of global exports [2] - The province's strategy is shifting towards a comprehensive competitive advantage in technology, brand, quality, and service, with over one-third of electromechanical product exports being self-branded [2] Green Trade Initiatives - Shandong's "new three samples" products are expected to see a 37% increase in exports by 2025, with electric vehicle exports projected to grow by 126% [2] - Customs is enhancing responses to green trade barriers and integrating various data sources to support carbon emission calculations and facilitate green cross-border trade [2]

展望未来，海南九芝堂药业将继续坚守创新初心，不断筑牢技术壁垒，以特色生物医药产业发展为重要 抓手，既要守护好海南珍贵的南药黎药文化遗产，也要为海南自贸港高新技术产业升级、热带特色高效 农业与生物医药产业深度融合发展贡献积极力量，书写"科技赋能特色产业"的发展新篇章。 作为承载"中华老字号"深厚底蕴的企业，九芝堂始终坚守创新驱动发展战略，在医药研发、产业升级等 多个领域持续突破，取得一系列关键性进展，为公司未来增长拓展了广阔空间。 近日，九芝堂全资子公司海南九芝堂药业顺利通过海南省科学技术厅"高新技术种子企业"认证，正式跻 身海南省高新技术"精英行动"企业体系，成为海南自贸港科技创新领域重点培育的后备力量。据悉，高 新技术种子企业是海南省为加快构建现代产业体系、助推自贸港高质量发展而遴选的核心培育对象，堪 称全省高新技术产业发展的"潜力标杆"。此次海南九芝堂药业成功入选，不仅是省级主管部门对公司在 创新开发领域不懈努力与丰硕成果的高度认可，更为企业高质量发展注入了强劲动力。 海南九芝堂药业始终以"传承南药黎药文化、创新发展医药产业"为核心使命，在特色药用资源开发领域 持续深耕。针对裸花紫珠等海南特色南药黎药品种 ...

Economic Overview - In 2025, Shanghai's GDP reached 56,708.71 billion yuan, reflecting a year-on-year growth of 5.4% in real terms [1] - The industrial added value in Shanghai grew by 5.0% year-on-year, with the total industrial output value increasing by 4.6% [1] Manufacturing Sector Performance - The manufacturing output of key industries in Shanghai saw significant growth, with the railway, shipbuilding, aerospace, and other transportation equipment manufacturing increasing by 15.8% [1] - The electrical machinery and equipment manufacturing sector grew by 11.1%, while the automotive manufacturing sector saw a 7.8% increase [1] - The computer, communication, and other electronic equipment manufacturing industries experienced a growth of 7.7% [1] Investment Trends - Industrial investment in Shanghai rose by 20.0% year-on-year, outpacing the overall fixed asset investment growth by 15.4 percentage points [1] Strategic Emerging Industries - The output value of Shanghai's three leading industries in manufacturing grew by 9.6%, surpassing 2 trillion yuan [2] - The integrated circuit manufacturing sector saw a growth of 15.1%, while the artificial intelligence manufacturing sector grew by 13.6% [2] - The strategic emerging industries in Shanghai experienced a year-on-year growth of 6.5%, with the new energy sector growing by 12.9% and high-end equipment manufacturing increasing by 11.1% [2] Industrial Development Strategy - Shanghai aims to build a modern industrial system characterized by "2+3+6+6," focusing on advanced manufacturing as the backbone [3] - The strategy emphasizes enhancing international competitiveness and supporting technological innovation while maintaining a reasonable industrial structure [3] - The three leading industries identified for accelerated development are integrated circuits, biomedicine, and artificial intelligence [3] AI and Integrated Circuit Industry - Shanghai has established a comprehensive integrated circuit industry chain, fostering leading enterprises across various segments, including chip design and manufacturing [5] - The city is home to 35 listed companies in the Science and Technology Innovation Board, leading the nation in chip design and manufacturing [5] - Recent developments include the rapid IPO of AI companies, such as MiniMax, which became the fastest AI company to go public globally [3][5]

英矽智能(03696)早盘涨近5%，截至发稿，涨3.68%，报55港元，成交额2152.11万港元。 根据协议条款，英矽智能将授予衡泰生物对ISM8969在全球范围内进行研究、开发、注册、生产和商业 化的50%权利。与此同时，英矽智能有权获得逾5亿港币的预付款及里程碑付款，包括一笔预计将在协 议生效日起30日内支付的7800万港币预付款。 消息面上，英矽智能近日发布公告称，与衡泰生物就ISM8969项目达成共同开发合作协议。基于这一独 家战略伙伴关系，双方将共同加速推进ISM8969的全球开发，这是一款口服且具备穿透血脑屏障性质的 新型NLRP3抑制剂，拟用于中枢神经系统疾病治疗。 ...

齐鲁晚报.齐鲁壹点夏侯凤超李梦瑶杜春娜于泊升 1月20日，济南市人大代表，济南市科技局党组书记、局长黄波在接受齐鲁晚报.齐鲁壹点采访时表示，2026年，市科技局将以"项目赋能年"为总牵引，紧 扣建设全国重要科技强市目标，扎实推动科技创新与产业创新深度融合，为强省会建设筑牢科技根基。 力争今年科技型中小企业 数量突破1万家 2025年，济南市科技系统以"项目提升年"为抓手，围绕"13+34"产业链体系，在强产业、育主体、搭平台、促转化等方面精准发力，多项工作取得阶段性 成效，为高质量发展注入了强劲动能。 "2026年，我们坚持围绕产业干，促进科技创新和产业创新深度融合，以科技创新引领新质生产力发展。"黄波表示，将进一步强化企业创新主体地位，把 培育科技型企业作为重中之重，实施科技型企业登峰计划，持续完善"科技型中小企业-高新技术企业-科技领军企业"梯次培育体系，推动企业实现"微成 长、小升高、高变强"，建立企业培育库，提供"一对一"精准服务，力争今年科技型中小企业数量突破1万家，科技领军企业实现零的突破。 深化"揭榜挂帅"机制，聚焦汽车电子、集成电路、人形机器人等重点产业，支持龙头企业牵头组建创新联合体，攻坚产 ...